Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Immuneering Corporation (NASDAQ:IMRX) has received a consensus rating of "Moderate Buy" from brokerages, with one sell recommendation and four buy recommendations among five analysts.
• Recent insider transactions include significant share purchases by directors, with one increasing their position by 1,396.03% and another by 22.37%.
• Immuneering's stock has seen a 10.4% decline, with a current trading price of $5.37, compared to a 12-month high of $6.35 and a low of $1.10.

Shares of Immuneering Corporation (NASDAQ:IMRX - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $13.00.

A number of brokerages have recently weighed in on IMRX. Needham & Company LLC reissued a "buy" rating and set a $8.00 price target on shares of Immuneering in a research report on Tuesday, August 26th. Mizuho upped their price target on shares of Immuneering from $8.00 to $10.00 and gave the stock an "outperform" rating in a research note on Wednesday, June 18th. Finally, Chardan Capital reiterated a "buy" rating and set a $13.00 target price on shares of Immuneering in a research report on Thursday, August 14th.

Immuneering Stock Performance

Shares of NASDAQ:IMRX traded up $0.47 during trading on Thursday, hitting $5.98. The company's stock had a trading volume of 630,130 shares, compared to its average volume of 1,230,043. Immuneering has a fifty-two week low of $1.10 and a fifty-two week high of $6.35. The company has a market capitalization of $217.19 million, a PE ratio of -3.15 and a beta of 0.43. The business has a 50 day moving average price of $4.16 and a two-hundred day moving average price of $2.53.

Immuneering (NASDAQ:IMRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). As a group, equities analysts expect that Immuneering will post -1.86 earnings per share for the current fiscal year.

Insider Transactions at Immuneering

In related news, Director Peter Feinberg bought 25,000 shares of the stock in a transaction on Wednesday, June 18th. The shares were bought at an average cost of $2.53 per share, for a total transaction of $63,250.00. Following the purchase, the director owned 136,766 shares of the company's stock, valued at $346,017.98. This trade represents a 22.37% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Thomas J. Schall purchased 9,500 shares of the business's stock in a transaction dated Friday, June 27th. The stock was bought at an average cost of $3.66 per share, with a total value of $34,770.00. Following the completion of the acquisition, the director owned 52,885 shares of the company's stock, valued at approximately $193,559.10. The trade was a 21.90% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 127,507 shares of company stock valued at $334,318. Corporate insiders own 22.90% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC lifted its stake in shares of Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company's stock valued at $776,000 after buying an additional 4,458 shares in the last quarter. Southport Management L.L.C. boosted its position in shares of Immuneering by 4.9% in the fourth quarter. Southport Management L.L.C. now owns 215,000 shares of the company's stock worth $473,000 after purchasing an additional 10,000 shares during the period. Two Sigma Investments LP raised its stake in Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company's stock valued at $111,000 after purchasing an additional 10,126 shares in the last quarter. Tang Capital Management LLC purchased a new stake in shares of Immuneering in the fourth quarter valued at $27,000. Finally, HighTower Advisors LLC increased its position in Immuneering by 17.7% during the 1st quarter. HighTower Advisors LLC now owns 83,960 shares of the company's stock valued at $128,000 after purchasing an additional 12,600 shares during the period. Institutional investors own 67.65% of the company's stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.